GLP-T

GLP-T (site product code) corresponds to tirzepatide, a synthetic 39-amino-acid peptide engineered as a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Published research has examined its interaction with these two incretin-receptor pathways in metabolic and glycemic signaling models. The summary below reflects the published literature and is provided for research reference only — it does not describe an intended effect of this product in humans or animals.

What is GLP-T?

Lyophilized — MUST BE RECONSTITUTED. GLP-T is a synthetic peptide related to compounds studied in metabolic and signaling research. It is designed as a dual-acting peptide built on a modified GIP peptide backbone that also activates GLP-1 receptor pathways, incorporating a fatty-diacid modification reported to extend circulating half-life via albumin binding in the originating research program. Researchers use compounds like this to better understand how dual-incretin-pathway peptides interact with biological signaling systems in controlled laboratory environments. Current published research is drawn from preclinical and clinical-trial settings, and no conclusions have been established for use of this product outside of laboratory research.

Chemical Identity

Full compound data: PubChem CID 156588324 (pubchem.ncbi.nlm.nih.gov/compound/156588324)

Purity & Quality

First Class Science supplies GLP-T at 99% purity, verified by independent third-party HPLC testing and mass spectrometry. A Certificate of Analysis is available for every batch at https://firstclassscience.com/certificate-of-analysis/.

Store lyophilised compound at −20°C for long-term stability. Refrigerate at 2–8°C after reconstitution and use within 4–6 weeks.

Important: This item is manufactured strictly for research purposes. It is not intended for human or veterinary use and is distributed solely for laboratory and scientific investigation.

GLP-T Research

Research Applications

Dual Incretin Receptor Signaling

Published research has examined this class of molecule’s balanced activity at both the GIP and GLP-1 receptors, a pattern study authors describe as distinct from single-pathway GLP-1 receptor agonists studied previously. Researchers have proposed that combined GIP/GLP-1 signaling may engage complementary downstream pathways relative to activating either receptor alone.

Glycemic & Metabolic Research Models

Published clinical and preclinical research on this peptide class has reported effects on glycemic and body-weight measures in the specific populations and models studied. This research is referenced here strictly as published third-party literature on the compound class and does not describe an intended effect of this product.
Disclaimer: The research summarized above is drawn from third-party published studies conducted in animal, in vitro, or non-U.S. clinical contexts. It is provided for research and educational reference only and does not describe an intended use, effect, or benefit of this product for any person or animal.

⊗ ALL ITEMS ARE SOLD FOR RESEARCH USE ONLY. This category covers strictly in vitro laboratory testing and scientific experimentation. Content on this site is for education only and does not authorize human or animal use of any kind, which is prohibited by law. Only trained, licensed professionals should handle these materials. Nothing sold here qualifies as a drug, food, or cosmetic, and none of it may be labeled, advertised, or used as such.